PDGFRA and gastrointestinal stromal tumor: While imatinib is highly potent against KIT exon 11 mutant GIST and also shows activity against some PDGFRA activation loop (AL) mutations, the PDGFRA-D842V mutation has for more than a decade been notoriously unresponsive to any known kinase inhibitor3,4,6–8.